Arrowhead Pharmaceuticals, Inc.

LSE:0HI3 Stock Report

Market Cap: US$2.4b

Arrowhead Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Chris Anzalone

Chief executive officer

US$9.9m

Total compensation

CEO salary percentage9.1%
CEO tenure17yrs
CEO ownership3.0%
Management average tenure6.5yrs
Board average tenure14.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Anzalone's remuneration changed compared to Arrowhead Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$599m

Jun 30 2024n/an/a

-US$539m

Mar 31 2024n/an/a

-US$471m

Dec 31 2023n/an/a

-US$297m

Sep 30 2023US$10mUS$903k

-US$205m

Jun 30 2023n/an/a

-US$181m

Mar 31 2023n/an/a

-US$150m

Dec 31 2022n/an/a

-US$155m

Sep 30 2022US$12mUS$863k

-US$176m

Jun 30 2022n/an/a

-US$154m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$183m

Sep 30 2021US$25mUS$837k

-US$141m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020n/an/a

-US$103m

Sep 30 2020US$14mUS$786k

-US$85m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

US$10m

Dec 31 2019n/an/a

US$53m

Sep 30 2019US$2mUS$674k

US$68m

Jun 30 2019n/an/a

US$46m

Mar 31 2019n/an/a

US$10m

Dec 31 2018n/an/a

-US$29m

Sep 30 2018US$2mUS$643k

-US$54m

Compensation vs Market: Chris's total compensation ($USD9.92M) is above average for companies of similar size in the UK market ($USD3.04M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Anzalone (55 yo)

17yrs

Tenure

US$9,918,093

Compensation

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Anzalone
CEO, President & Director17yrsUS$9.92m2.99%
$ 72.9m
Kenneth Myszkowski
Chief Financial Officer14.8yrsUS$3.12m0.19%
$ 4.6m
Patrick O'Brien
COO, General Counsel & Secretary10yrsUS$3.31m0.23%
$ 5.6m
James Hamilton
Chief of Discovery & Translational Medicineno dataUS$3.05m0.16%
$ 4.0m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datano datano data
Vincent Anzalone
Head of Investor Relations & VPno datano datano data
Howard Lovy
Director of Communications19.3yrsno datano data
Bruce Given
Chief Medical Scientistless than a yearUS$16.34mno data
Mark Seefeld
Head of Toxicology & VPno datano datano data
Aaron Tan
Head of Tax2.9yrsno datano data
Andy Davis
SVP of Cardiovascular & Head of Metabolic Franchiseless than a yearno datano data
Nadia Meshkova
VP & Treasurer2.9yrsno datano data

6.5yrs

Average Tenure

59yo

Average Age

Experienced Management: 0HI3's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Anzalone
CEO, President & Director17yrsUS$9.92m2.99%
$ 72.9m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono datano datano data
Douglass Given
Chairman of the Board14.1yrsUS$474.60k0.12%
$ 2.9m
Michael Perry
Independent Lead Director13yrsUS$459.60k0.074%
$ 1.8m
William Waddill
Independent Director6.9yrsUS$469.60k0.032%
$ 792.6k
Ching-Lung Lai
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Robert Gish
Chairman of Hepatitis B Clinical Advisory Boardno datano datano data
Mauro Ferrari
Independent Director14.3yrsUS$459.60k0.037%
$ 898.9k
Jeffrey Teckman
Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Boardno datano datano data
Stephen Locarnini
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Johnson Lau
Member of Hepatitis B Clinical Advisory Boardno datano datano data
Carlo Ferrari
Member of Hepatitis B Clinical Advisory Boardno datano datano data

14.1yrs

Average Tenure

65yo

Average Age

Experienced Board: 0HI3's board of directors are seasoned and experienced ( 14.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 12:56
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arrowhead Pharmaceuticals, Inc. is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Ying HuangBarclays
Jason Matthew GerberryBofA Global Research